Skin clearance rates were maintained at five years with 55.5 percent of patients achieving an Investigator’s Global Assessment score of 0 and 53 percent achieving Psoriasis Area Severity Index 100 response in VOYAGE 2 TREMFYA, the first and only selective interleukin (IL)-23 inhibitor therapy approved for both PsO and PsA, improved overall PsA disease activity as evaluated by composite disease activity scores, and PsA axial symptoms as evaluated by the Bath Ankylosing Spondylitis Disease Activity Index in DISCOVER-1 and -2
